secwatch.observer — SEC 8-K summary
======================================

Issuer:     Anebulo Pharmaceuticals, Inc. (ANEB)
CIK:        0001815974
Form:       8-K
Filed at:   2024-12-23T23:59:59+00:00
Accession:  0001493152-24-051853
Event type: other_material
Sentiment:  positive
Materiality: 0.80
Item codes: 1.01, 3.02, 5.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Anebulo raises $15M via private placement, FDA supports development of IV selonabant for pediatric cannabis toxicity
--------------------------------------------------------------------------------

- Raised $15M gross from sale of 15.2M shares at $0.99/share; change of control as director Aron English now owns >50% of common stock.
- FDA acknowledged unmet need for pediatric cannabis toxicity and proposed close collaboration to efficiently advance IV selonabant program.
- Plans to begin Phase 1 SAD study of IV selonabant in healthy adults in 1H 2025.
- Will modify Loan & Security Agreement with 22NW and JFL Capital: reduce max loan to ~$3M, remove securitization.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1815974/000149315224051853/0001493152-24-051853-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1815974/000149315224051853/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-24-051853

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer